FAST NEWS: RemeGen scales back A-share fundraising plan
The Latest: Novel drug maker RemeGen Co. Ltd. (9995.HK; 688331.SH) announced Wednesday that it has reduced its fundraising target through a planned issue of new A-shares from a previous 2.55 billion yuan ($350…
RemeGen hopes for pain relief from expanded drug uses
The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
Henlius finds elixir in first profits, scraps A-share IPO
The drug maker said last week it will halt plans for a second listing on China’s STAR Market, the same day it announced its first-ever interim profit since its 2019…
Lepu Biopharma gets taste of spring with first revenues
The ADC-focused drug company logged its first-ever sales late last year, kicking of the next phase of its development Key Takeaways: Lepu Biopharma began to sell its first product last…
Kelun-Biotech hopes for IPO booster from new Merck partnership
The company welcomed Merck as new shareholder not long after the pair signed a lucrative licensing agreement for its cutting-edge ADC cancer treatment Key Takeaways: Despite a lack of products…
InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing
The Hong Kong-traded company will become the latest from the cash-challenged pharma sector to make a second listing on the A-share market Key Takeaways: InnoCare Pharma’s A-share IPO will make…
Lacking Revenue, Lepu Biopharma Chases IPO to Revive War Chest
The cutting-edge cancer treatment company has not generated any revenue from its products, and only has enough money to last another three months Key takeaways: Lepu Biopharma has yet to…
Recent Articles
FAST NEWS: RemeGen scales back A-share fundraising plan
9995.HK
688331.SHG
RemeGen hopes for pain relief from expanded drug uses
9995.HK
688331.SHG
RELATED ARTICLES
-
Akeso marks profit milestone with swift rights issue
9926.HK -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Clinical trials come up short again for Alphamab Oncology
9966.HK
-
Everest reaches new heights on growing drug sales
1952.HK
